What Is Bacillibactin? Definition and What Research Reports

Definition

Bacillibactin is a catecholate-type siderophore: a small, high-affinity iron-chelating molecule produced by Bacillus subtilis and closely related species such as Bacillus velezensis, Bacillus amyloliquefaciens and Bacillus halotolerans. Structurally it is a cyclic trimer built from repeating 2,3-dihydroxybenzoate–glycine–threonine units, assembled by non-ribosomal peptide synthetase (NRPS) enzymes rather than by the ribosome. Its biological role, as described in the microbiology literature, is to scavenge ferric iron from the surrounding environment so the producing bacterium can acquire iron in iron-limited conditions and compete with neighbouring microbes. Bacillibactin is a microbial natural product studied in soil, plant, marine and clinical-isolate contexts — it is not a therapeutic peptide, not an approved drug, and has no human clinical dosing literature in the sources reviewed here. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question.

What Class of Molecule Is It?

A non-ribosomal peptide, not a signalling peptide

Bacillibactin belongs to the non-ribosomal peptide (NRP) family. NRPs are assembled enzymatically on large modular NRPS machines, which is why they can contain building blocks that ribosomal peptides cannot — in bacillibactin's case, the catechol group 2,3-dihydroxybenzoic acid, plus ester linkages that form the macrocyclic trilactone backbone. That chemistry is what gives the molecule its extremely tight grip on ferric iron.

Because of this, bacillibactin sits in a very different category from the research peptides most often discussed in peptide glossaries. It is not a growth-factor fragment, not a receptor agonist studied for metabolic or tissue endpoints, and not a compound with published human administration protocols. It appears in peptide-adjacent literature because of how it is made (non-ribosomal peptide chemistry) and what it does at the molecular level (metal coordination), not because of any human use.

Where it comes from

The biosynthetic gene cluster encoding bacillibactin is widespread across the Bacillus subtilis group, which is why it turns up repeatedly in whole-genome sequencing papers describing new environmental isolates. Producing strains have been recovered from soil, from plant tissue as endophytes, and from marine sponge material, among other sources.

How the Term Is Used in Research

In the published literature, "bacillibactin" is used in three main ways:

• As a named secondary metabolite in genome-mining reports, where antiSMASH-style analysis lists the biosynthetic gene clusters a newly sequenced Bacillus strain carries.
• As a mechanistic variable in studies of microbial antagonism, where iron sequestration is tested as a reason one organism suppresses another.
• As a structural scaffold in natural-product chemistry, where new analogues of the parent molecule are isolated and characterised.

What the Published Literature Reports

Researchers described two new bacillibactin analogues, named bacillibactins E and F, isolated from a marine sponge-associated Bacillus sp., in a natural-products study of that strain's metabolites (PMID 33337146). In a separate line of work, the study of Bacillus amyloliquefaciens MBI600 reported that bacillibactin itself showed direct antibiotic activity, which the authors interpreted as broadening the strain's biocontrol range beyond iron competition alone (PMID 34378986). Iron-centred antagonism was examined more directly in work on Bacillus subtilis and Pseudomonas marginalis, where researchers reported that competition for iron shaped the metabolic antagonism between the two organisms (PMID 38365234).

A bacteriology study set out to define the expression, production and signalling roles of specialised metabolites — bacillibactin among the metabolites considered — across Bacillus subtilis differentiation states, reporting that these compounds are produced in a stage-dependent way rather than uniformly (PMID 34460312). Together these papers frame bacillibactin as a competition and iron-acquisition molecule whose production is regulated with the producing cell's physiological state.

Genome-mining and biocontrol reports

Much of the remaining literature is descriptive genomics: sequencing a Bacillus isolate, cataloguing its secondary-metabolite gene clusters, and testing the strain against target pathogens. The table below summarises examples in which the studies characterised siderophore or specialised-metabolite capacity alongside antimicrobial testing.

Human Safety and Adverse Events: What Studies Report

The verified literature reviewed for this entry is microbiological and agricultural: whole-genome sequencing, natural-product isolation, and in vitro or plant-based antagonism testing. No human trial, human dosing schedule, or human adverse-event dataset for bacillibactin appears in these sources, and none is described here. Statements about safety in people cannot be drawn from strain-level biocontrol or genome-mining reports such as those on Bacillus velezensis LS69 (PMID 28323017) or Bacillus subtilis KC14-1 (PMID 40165078), because those studies measured microbial inhibition rather than mammalian outcomes.

Limitations of the Evidence

• Strain-level, not molecule-level. Many reports identify a bacillibactin gene cluster in a genome without isolating the purified molecule or attributing an observed effect to it specifically.
• Context-dependent activity. Iron availability drives siderophore behaviour, so results reported under iron-limited laboratory conditions (PMID 38365234) may not transfer to other environments.
• No translational data. Direct antibiotic activity described for bacillibactin in a biocontrol setting (PMID 34378986) is an in vitro and agricultural finding, not a clinical one.

Related Terms

• Siderophore — any secreted molecule that binds iron with high affinity for microbial uptake.
• Catecholate — the chemical class of iron-binding group found in bacillibactin and in enterobactin, its Escherichia coli counterpart.
• NRPS — non-ribosomal peptide synthetase, the enzyme family that assembles bacillibactin.
• Surfactin — another Bacillus non-ribosomal lipopeptide, reported in genome-guided work on Bacillus halotolerans AQ11M9 (PMID 39408762).

References

• Bacillibactins E and F from a Marine Sponge-Associated Bacillus sp (Journal of Natural Products, 2021)
• Direct Antibiotic Activity of Bacillibactin Broadens the Biocontrol Range of Bacillus amyloliquefaciens MBI600 (mSphere, 2021)
• Competition for iron shapes metabolic antagonism between Bacillus subtilis and Pseudomonas marginalis (The ISME Journal, 2024)
• Defining the Expression, Production, and Signaling Roles of Specialized Metabolites during Bacillus subtilis Differentiation (Journal of Bacteriology, 2021)
• Whole-genome sequencing of Bacillus velezensis LS69, a strain with a broad inhibitory spectrum against pathogenic bacteria (Journal of Biotechnology, 2017)
• Genomic, Antimicrobial, and Aphicidal Traits of Bacillus velezensis ATR2, and Its Biocontrol Potential against Ginger Rhizome Rot Disease Caused by Bacillus pumilus (Microorganisms, 2021)
• Whole genome-sequence analysis of Bacillus subtilis strain KC14-1 with broad-spectrum antifungal activity (BMC Genomics, 2025)
• Genomic and biological control of Sclerotinia sclerotiorum using an extracellular extract from Bacillus velezensis 20507 (Frontiers in Microbiology, 2024)
• Bacillus velezensis NC-B4 as a promising antifungal agent for biocontrol of Candida auris (Frontiers in Cellular and Infection Microbiology, 2025)
• Genome-Guided Identification of Surfactin-Producing Bacillus halotolerans AQ11M9 with Anti-Candida auris Potential (International Journal of Molecular Sciences, 2024)
• Insights into Genomic Features and Potential Biotechnological Applications of Bacillus halotolerans Strain HGR5 (Polish Journal of Microbiology, 2023)
• Genomic Analysis of Endophytic Bacillus cereus T4S and Its Plant Growth-Promoting Traits (Plants, 2021)